The ferocity of China’s biopharmaceutical investment boom this year – fuelled by record-breaking licensing of commercial rights to global giants…
Read More »novel drugs
Jiangsu Hengrui Pharmaceuticals and Hansoh Pharmaceutical Group, two of China’s largest drug makers, are expected to report significantly improved profits,…
Read More »
China’s cost and efficiency advantages in drug development have been recognised at the world’s largest cancer research conference in the…
Read More »
Jiangsu Hengrui Pharmaceuticals, a leading Chinese developer of novel drugs that recently received approval to go public in Hong Kong,…
Read More »